Juvenile | sciencenewsnet.in

Breaking News

Technological Breakthrough in Carbon Nanotube Applications for Battery Dry Process

Lack of control at work identified as cause for physician burnout and attrition

Expanding HPV vaccination to all adults aged 27-45 years unlikely to be cost-effective or efficient for HPV-related cancer prevention

University Student’s Start-Up Expands, Connecting Small Coffee Farmers to the World

FSU physicists will study nuclear reactions of stars with support from National Science Foundation

Warning: don’t miss Thanksgiving dinner, it’s more meaningful than you think

Roswell Park Launches First-of-Its-Kind Oncology Training Program for Nurse-Scientists With $2M NCI Grant

UT Southwestern brings first-of-its-kind radiation oncology to new $177M campus in Fort Worth Medical District

Tips and recipes for a healthy holiday season from a doctor and a dietitian

X-ray Measurements Reveal an Unexpected Role for Copper in Photocatalysts

26 Nov, 2024

Study First to Explore ‘Walking’ Sharks on the Move in Early Life Stages

August 18, 2022 sarah JonasResearch Results

A newly-discovered walking shark that breaks all of the rules for survival is the focus of a first-of-its-kind study that examined differences in walking and swimming in neonate (newly-hatched) and juvenile walking sharks. Despite dissimilarities in body shapes – neonates have bulging bellies and juveniles are slender – the three aquatic gaits they use (slow-to-medium walking, fast-walking and swimming) did not differ. Kinematics between neonate and juvenile epaulette sharks did not alter during development.

Early Combined Treatment with Biologic and Conventional DMARDs Could be Effective for Polyarticular Juvenile Arthritis

November 2, 2021 sarah JonasResearch Results

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, found that patients started on early, aggressive treatment with a combination of biologic and conventional disease modifying antirheumatic drugs (DMARDs) achieved clinically inactive disease in children with polyarticular juvenile idiopathic arthritis (JIA) more frequently compared to other treatment plans 24 months after starting treatment.